Stock Scorer

Bolt Biotherapeutics, Inc. (BOLT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 2M 4M 6M Q3 '21: 752K Q4 '21: 508K Q1 '22: 813K Q2 '22: 1.4M Q3 '22: 2.1M Q4 '22: 1.4M Q1 '23: 1.8M Q2 '23: 1.4M Q3 '23: 2.5M Q4 '23: 2.1M Q1 '24: 5.3M Q2 '24: 1.3M Q3 '24: 1.1M Q4 '24: 0 Q1 '25: 1.2M Q2 '25: 1.8M Q3 '25: 2.2M Q4 '25: 2.5M Q1 '26: 26K Q2 '26: 5K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -23.5M Q4 '21: -27.1M Q1 '22: -23.9M Q2 '22: -23.1M Q3 '22: -22.3M Q4 '22: -21M Q1 '23: -18.4M Q2 '23: -19.8M Q3 '23: -18.2M Q4 '23: -19.8M Q1 '24: -17.1M Q2 '24: -22.6M Q3 '24: -16.4M Q4 '24: -16.9M Q1 '25: -12.1M Q2 '25: -9.2M Q3 '25: -7.7M Q4 '25: -7.1M Q1 '26: -7.6M Q2 '26: -8.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q3 '21: -23.4M Q4 '21: -27.2M Q1 '22: -23.7M Q2 '22: -22.7M Q3 '22: -21.8M Q4 '22: -20M Q1 '23: -17M Q2 '23: -18.1M Q3 '23: -16.3M Q4 '23: -17.9M Q1 '24: -10.8M Q2 '24: -21.2M Q3 '24: -15.2M Q4 '24: -15.9M Q1 '25: -11M Q2 '25: -8.6M Q3 '25: -7.1M Q4 '25: -6.6M Q1 '26: -7.2M Q2 '26: -7.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -18.7M Q4 '21: -17.8M Q1 '22: -24.3M Q2 '22: -20.8M Q3 '22: -13.5M Q4 '22: -18M Q1 '23: -23.4M Q2 '23: -15.1M Q3 '23: -16.7M Q4 '23: -14.3M Q1 '24: -16.8M Q2 '24: -16.1M Q3 '24: -14M Q4 '24: -14.4M Q1 '25: -13.4M Q2 '25: -9.6M Q3 '25: -9.7M Q4 '25: -7.2M Q1 '26: -8M Q2 '26: -6.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '20: -13.7M Q4 '20: -13.8M Q1 '21: -16.6M Q2 '21: -4.7M Q3 '21: -19.7M Q4 '21: -18.4M Q1 '22: -24.9M Q2 '22: -21.2M Q3 '22: -14.2M Q4 '22: -18.1M Q1 '23: -23.4M Q2 '23: -15.1M Q3 '23: -16.9M Q4 '23: -14.3M Q1 '24: -16.8M Q2 '24: -16.1M Q3 '24: -14M Q4 '24: -14.4M Q3 '25: -9.8M Q4 '25: -7.2M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '20: 1.9M Q2 '20: 1.9M Q3 '20: 2M Q1 '21: 21.5M Q2 '21: 36.6M Q3 '21: 37.2M Q1 '22: 37.1M Q2 '22: 37.3M Q3 '22: 37.5M Q1 '23: 37.7M Q2 '23: 37.8M Q3 '23: 37.9M Q1 '24: 38.1M Q2 '24: 1.9M Q3 '24: 1.9M Q1 '25: 1.9M Q2 '25: 1.9M Q3 '25: 1.9M Q1 '26: 1.7M Q2 '26: 1.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q3 '21: -17.11 Q4 '21: -3.14 Q1 '22: -2.64 Q2 '22: -2.61 Q3 '22: -2.56 Q4 '22: -2.36 Q1 '23: -2.17 Q2 '23: -2.04 Q3 '23: -1.89 Q4 '23: -1.83 Q1 '24: -1.66 Q2 '24: -12.30 Q3 '24: -19.80 Q4 '24: -27.66 Q1 '25: -33.14 Q2 '25: -26.48 Q3 '25: -22.27 Q4 '25: -17.85 Q1 '26: -16.40 Q2 '26: -16.51 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for BOLT: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.